COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND AN HLA-G T CELL BISPECIFIC ANTIBODY
Application
US20260077044A1
Kind: A1
Mar 19, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Meher MAJETY, Carina HAGE, Laura CODARRI DEAK, Valeria Gonzalez NICOLINI
Abstract
The invention relates to combination therapies employing an anti-PD1/anti-LAG3 bispecific antibody and an HLA-G T cell-activating bispecific antibody, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
CPC Classifications
A61K 39/39558
A61P 35/00
A61K 2039/507
Filing Date
2025-08-26
Application No.
19310373